Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT

详细信息    查看全文

• 作者：Vincent P. Groot¹ ; ² ; Hjalmar C. van Santvoort³ ; ⁴ ; Steffi J.E. Rombouts¹ ; Jeroen Hagendoorn¹ ; Inne H.M. Borel Rinkes¹ ; Marco van Vulpen⁵ ; Joseph M. Herman⁶ ; Christopher L. Wolfgang² ; Marc G. Besselink⁴ ; I. Quintus Molenaar¹ ; ^{i.q.molenaar@umcutrecht.nl}
• 刊名：HPB
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：19
• 期：2
• 页码：83-92
• 全文大小：756 K
• 卷排序：19

文摘

The majority of patients who have undergone a pancreatic resection for pancreatic cancer develop disease recurrence within two years. In around 30% of these patients, isolated local recurrence (ILR) is found. The aim of this study was to systematically review treatment options for this subgroup of patients.MethodsA systematic search was performed in PubMed, Embase and the Cochrane Library. Studies reporting on the treatment of ILR after initial curative-intent resection of primary pancreatic cancer were included. Primary endpoints were morbidity, mortality and survival after ILR treatment.ResultsAfter screening 1152 studies, 18 studies reporting on 313 patients undergoing treatment for ILR were included. Treatment options for ILR included surgical re-resection (8 studies, 100 patients), chemoradiotherapy (7 studies, 153 patients) and stereotactic body radiation therapy (SBRT) (4 studies, 60 patients). Morbidity and mortality were reported for re-resection (29% and 1%, respectively), chemoradiotherapy (54% and 0%) and SBRT (3% and 1%). Most patients had a prolonged disease-free interval before recurrence. Median survival after treatment of ILR of up to 32, 19 and 16 months was reported for re-resection, chemoradiotherapy and SBRT, respectively.ConclusionIn selected patients, treatment of ILR following pancreatic resection for pancreatic cancer seems safe, feasible and associated with relatively good survival.